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ABSTRACT
Introduction: Hypoparathyroidism is a rare endocrine disease, most frequently due to surgical damage
to the parathyroids. Hypocalcemia, caused by this disease, can affect the function of most organs, but in
particular neurological, cognitive, muscular, and cardiac functions. The long term consequences of
hypoparathyroidism can include ectopic calcifications, renal complications and impaired quality of life.
At last, in hypoparathyroidism higher bone mineral density and lower bone turnover markers are
described, and these factors could have an impact on the risk of fracture, but still it is unclear.
Areas covered: This disease is usually treated with calcium, calcitriol, or an active vitamin D analog.
Although the standard therapy can adequately control patients, sometimes very high doses are
required to maintain serum calcium levels in the normal range, with poor compliance and risk of
long term complications. This article analyzes the recent therapeutic approach with the use of recom-
binant human PTH (rhPTH), through a systematic review of English articles regarding the use of rhPTH
(1–84) and (1–34).
Expert opinion: The possibility of having a therapeutic alternative, such as the rhPTH could represent a
great opportunity. However, further studies are necessary to clarify several aspects especially regarding
long term effects of rhPTH.
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1. Introduction
Hypoparathyroidism is a rare metabolic disease caused either
by deficient or absent production of the parathyroid hormone
(PTH) by the parathyroid glands or by resistance to PTH in its
target tissues, called pseudohypoparathyroidism [1]. The most
common form of hypoparathyroidism is postsurgical hypo-
parathyroidism, followed by autoimmune, genetic, infiltrative,
or irradiative causes. Hypoparathyroidism is one of the few
endocrine diseases characterized by hyposecretion, whose
treatment, except in the United States, does not consist of
administration of the defective hormone. The conventional
treatment consists of supplementations with calcium and cal-
citriol or other active vitamin D analogs, and although many
patients are adequately controlled, sometimes high doses are
necessary to control serum calcium concentration [1]. Large
doses of these supplements can cause long-term complica-
tions, such as renal impairment and extraskeletal calcifications
[2]. Moreover, conventional therapy with calcium and active
vitamin D has not proved to be capable to reverse abnormal-
ities in bone remodeling, typical of the disease, not providing
a physiological replacement remedy for the lack of PTH in
hypoparathyroidism. At last, many patients with chronic hypo-
parathyroidism report symptoms that suggest impaired qua-
lity of life [3], and current standard treatment in
hypoparathyroidism has not been demonstrated to be cap-
able to restore well-being in these patients [4].
Recently, several studies have investigated hormone repla-
cement therapy with recombinant human PTH (rhPTH) (1–84)
and with the N-terminal PTH fragment (rhPTH (1–34)) adminis-
tered by subcutaneous injection in hypoparathyroid patients,
not adequately controlled with conventional therapy. In
January 2015, the Food and Drug Administration (FDA)
approved, only in the USA, the use of rhPTH (1–84) for the
management of chronic hypoparathyroidism, not adequately
controlled with standard treatment, with a ‘black box’ warning
because of the potential risk of osteosarcoma, but without
limit of the duration of use [5,6].
The main clinical features of chronic hypoparathyroidism
are analyzed, in the following sections, in order to highlight
the issues that chronic treatment of this disease should face,
and subsequently, a systematic review of English articles,
regarding the use of rhPTH (1–84) and (1–34) in hypoparathy-
roid patients, is conducted.
1.1. Hypocalcemia
Physiologically, PTH is secreted by the parathyroid glands as
an 84-amino acid peptide, and serum calcium is the major
regulatory signal for secretion of PTH. Serum calcium concen-
tration has a very important role for several physiological
processes, and small deviations of serum calcium levels impair
a variety of cellular functions. Its concentration, indeed, is
normally maintained within a very narrow range [7]. Low
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extracellular ionized calcium level causes typical signs and
symptoms involving a large number of tissues and organ
systems, such as brain, muscles, and heart [8]. Signs and
symptoms of hypocalcemia in hypoparathyroidism are sum-
marized in Table 1 [1,3,9]. In addition to hypocalcemia, hyper-
phosphatemia is another consequence of hypoparathyroidism.
High phosphate levels are asymptomatic but can cause long
term complications such as ectopic mineralization in soft tis-
sues of the vascular, nervous, renal, and other organs, impair-
ing their function [2,7]. These ectopic calcifications can be
caused by the chronically elevated phosphate concentrations
and high calcium–phosphate product, due to the disease itself
and long-term treatments with calcium and calcitriol or other
active vitamin D analogs [2,3].
1.2. Bone manifestations in chronic hypoparathyroidism
One of the key regulators of the rate of bone remodeling is PTH,
and a reduction or absence of this hormone leads to a decrease in
bone resorption and then to a coupled reduction in bone forma-
tion. Over time, the balance between resorption and formation
favors the latter because bone mass increases in both cancellous
and cortical bone compartments [1]. Indeed, bonemineral density
(BMD), measured by dual-energy x-ray absorptiometry (DXA), is
usually above average in thesepatients [10–13]. Studies performed
with imaging with peripheral quantitative computed tomography
(pQCT) and high-resolution pQCT, as well as direct histomorpho-
metric analysis of bone by transiliac bone biopsy, showed that
both cortical and trabecular bone are impaired. Increased cortical
volumetric BMD (vBMD), decreased cortical porosity, and trabecu-
lar bone volume fraction associated to low bone turnover were
described [14–16]. Higher BMD in hypoparathyroidism is due in
large part to the increase in bone tissue volume rather than an
increase in the amount of mineral within the tissue [10,17].
The abnormally low bone remodeling and dense bone could
suggest that hypoparathyroid bone is hypermature, with an
impaired bone quality, and potentially more subject to fracture
than euparathyroid bone [2,18]. In this regard, some studies
evaluated the fracture risk in these patients, but there are con-
flicting results. Recently, Underbjerg et al. conducted a nation-
wide Danish survey, identifying 688 patients with postsurgical
hypoparathyroidism due to nonmalignant causes, treated with
standard treatment (calcium and vitamin D metabolites) for
more than 6 months. Each case was matched for age and sex
with three controls from the general population. The long-term
overall fracture risk was not different from controls, whereas the
risk of fractures in the upper extremities was significantly
decreased in patients with chronic hypoparathyroidism [19]. In
another Danish study, Underbjerg et al. identified 180 subjects
diagnosed with nonsurgical hypoparathyroidism between 1997
and 2012. Patients were compared with an age- and gender-
matched control group from the general population. Although
the overall fracture risk was similar between cases and controls,
patients with chronic hypoparathyroidism had a greater risk of
fractures in the upper extremities [20]. Therefore, further data on
bone strength and the risk of fractures are sorely needed, con-
sidering that the long-term effects of increased bone mass could
be beneficial, but low bone turnover could be possibly deleter-
ious to bone quality [3].
1.3. Renal complications in chronic hypoparathyroidism
Decreased PTH secretion or action on tubular functions
should cause hypercalciuria and reduced urinary phos-
phate excretion, but this is not generally described in
chronic hypoparathyroidism because the filtered load of
Article highlights
● Hypoparathyroidism is an endocrine disease characterized by hypo-
calcemia and hyperphosphatemia in presence of undetectable or
inappropriately low levels of parathyroid hormone (PTH).
● Conventional treatment of chronic hypoparathyroidism consists
mainly of calcium supplements and calcitriol, whose chronic use at
high dose can lead to long-term complications, particularly renal
impairment and ectopic calcifications.
● Several studies have recently investigated hormone replacement
therapy with rhPTH (1-34) and rhPTH (1-84), as treatment for patients
with chronic hypoparathyroidism not adequately controlled with
standard treatment.
● Some studies demonstrated that injections twice-a-day of rhPTH (1-
34) showed a good control of mean serum calcium levels, a reduction
in the need for calcium and active vitamin D supplements, but did
not obtain a significant reduction in 24-hour urinary calcium excre-
tion compared to standard therapy. Moreover, the studies with rhPTH
(1-34) therapy delivered by an infusion pump showed, instead, a near
normalization of the diurnal rhythm of serum calcium, and a signifi-
cant reduction of 24-hour urinary calcium excretion, compared with
twice-a-day injections subcutaneous of rhPTH (1-34).
● rhPTH (1-84) provides the natural hormone, lacking in this disorder,
and has an effective half-life longer than rhPTH (1-34). The studies
showed that this drug permits a reduction in the need for calcium
and active vitamin D supplements, maintaining normal mean serum
calcium levels compared to conventional therapy, a reduction in 24-
hour urinary calcium excretion at 24 weeks compared to baseline
(‘REPLACE’ trial), and showed significant transient reductions of 24-
hour urinary calcium excretion in long term study (6 years) compared
to baseline.
● Several future investigations are necessary regarding evaluation of
long-term efficacy and safety of rhPTH treatment.
This box summarizes key points contained in the article.
Table 1. Clinical manifestations of hypocalcemia in patients affected by
hypoparathyroidism.
Organ/system
target Clinical manifestations
Neuromuscular Fatigue, muscle weakness, muscle cramping (carpopedal
spasms), neuromuscular irritability, tetany, spams/
twitches, cramps, laryngospasm, stridor, bronchospasm
and wheezing, and Trousseau and Chvostek signs.
Neurological,
psychiatric
Paresthesia and numbness (especially around mouth,
fingers, and toes), seizures, poor memory and
concentration, confusion or disorientation, irritability,
depression, and anxiety.
Cardiovascular Congestive heart failure, arrhythmias, fast, slow, or
uneven heart rate, heart block, and ECG: prolonged QTc
interval.
Bone Fragility fractures
Gastrointestinal Constipation, abdominal cramps, and steatorrhea.
Respiratory Shortness of breath, wheezing, and throat tightness.
Ophthalmologic Papilledema, posterior subcapsular cataract, and corneal
calcifications.
Dental Hypoplastic teeth, enamel hypoplasia, delayed tooth
eruption, shortened premolar roots, and increased
dental caries.
Dermatologic Alopecia, dry skin, atopic eczema, and brittle nails.
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calcium is usually lower than normal, and hyperphospha-
temia leads to a greater filtered load of phosphate [2].
However, large amounts of calcium and calcitriol, or
other active vitamin D analogs, required for maintaining
normal serum calcium levels, can cause hypercalciuria and
long-term complications such as renal calcium deposition
(stones or calcinosis) and renal function impairment [7,18],
especially in those with episodes of treatment-induced
hypercalcemia [21].
1.4. Impairment of quality of life in hypoparathyroidism
Many patients affected by chronic hypoparathyroidism
describe symptoms that suggest impaired quality of life [1,2].
The symptoms include physical complaints such as fatigue,
muscle spasms, pain, and paresthesia; cognitive symptoms
such as ‘brain fog’ and inability to concentrate; and emotional
difficulties including depression and/or anxiety [7,18]. Some
studies showed that quality of life was lower than expected
norms independently by the etiology of the hypoparathyroid-
ism, the duration of disease, or the extent to which biochem-
ical control is achieved with calcium and active vitamin D
[4,17]. It is clear that chronic hypoparathyroidism can be asso-
ciated with impaired quality of life, but the nature of this
impairment and its relationship to biochemical control are
not well characterized.
Table 2 summarizes the main complications/comorbidities
of chronic hypoparathyroidism in adults.
2. Materials and methods
A systematic review of English articles, regarding the use of
rhPTH (1–84) and (1–34) in patients affected by chronic
hypoparathyroidism, using MEDLINE (1996–2016) was con-
ducted. Search terms included hypoparathyroidism, therapy,
parathyroid hormone, rhPTH (1–84), PTH (1–84), rhPTH (1–
34), and PTH (1–34). Randomized, open-label crossover trials;
double-blind (or not), randomized open-label studies; and
open-label studies, conducted in subjects affected by
chronic hypoparathyroidism, treated with rhPTH, were
included. All included studies had to quantitatively report
the outcomes of interest, such as effects of rhPTH on bone
metabolism, and/or BMD, and/or bone quality, and/or qual-
ity of life. Retrospective studies, letters, comments, editor-
ials, case report, review, expert opinion, and personal
communications were excluded. The following data were
extracted from studies that met the inclusion criteria:
study design, number of participants in each group, partici-
pants’ age, intervention, and outcomes (serum and urine
calcium, serum phosphorous, and bone markers levels;
BMD; calcium and calcitriol doses; and/or evaluation of
quality of life).
Due to heterogeneity in study design, different blinding
methods, and variable control arms, a meta-analysis was not
possible to compare the advantage of rhPTH over standard
treatment (vitamin D and calcium).
3. Results
Studies selected and analyzed were 23, including 9 studies
regarding rhPTH (1–34) treatment and 14 studies regarding
rhPTH (1–84) in patients affected by chronic hypoparathyr-
oidism. Studies on rhPTH (1–34) therapy included: one
pivotal, randomized crossover trial [22]; six randomized,
two-arm, open-label crossover studies [23–28]; and two
open-label studies [29,30]. Studies on rhPTH (1–84) therapy,
instead, included: one open-label, single-dose phase I study
[31]; four double-blind, randomized placebo-controlled stu-
dies [12,32–34]; three randomized open-label study [35–37];
and six open-label studies [10,13,38–41]. There were no
studies comparing the effects of rhPTH (1–34) and rhPTH
(1–84). Moreover, the administration way was different;
rhPTH (1–84) was administered as a single dose, whereas
rhPTH (1–34) was administered in variable dosing regimens,
such as once- or twice-daily or through pump delivery. Due
to the different study designs, the results are not directly
comparable.
Figure 1 shows flowchart for study selection.
3.1. Hormone replacement therapy with rhPTH (1–34)
for chronic hypoparathyroidism
rhPTH (1–34) has an identical sequence to the 34
N-terminal amino acids, the biologically active region, of
the human PTH [42]. rhPTH (1–34) affects calcium and
phosphate metabolism in a pattern consistent with the
known actions of endogenous PTH. When rhPTH (1–34)
20 µg is administered once daily, the serum calcium con-
centration increases transiently, beginning approximately
2 h after dosing and reaching a maximum concentration
Table 2. Complications/comorbidities of chronic hypoparathyroidism in adults.
Organ/system
target Principal mechanisms involved Clinical manifestations/instrumental alterations
Renal Extraskeletal calcifications related to elevated calcium–phosphate product
and hypercalciuria
Renal stones, renal calcifications, and impaired renal function
Bone Reduction in bone remodeling due to lack of PTH Increased bone mineral density measured by DEXA
Cardiovascular Calcium salt precipitation in vascular tissues Ischemic heart diseasea
CNS Extraskeletal calcifications related to elevated calcium–phosphate product Movement disorders, chorea, and parkinsonism
Neuropsychiatric Lack of PTH/disturbances in calcium–phosphate homeostasis Depression, bipolar disorders, and anxiety
Eyes Extraskeletal calcifications related to elevated calcium–phosphate product Cataractsa
Immunological Hypocalcemia can reduce activation of second messengers in neutrophils Infections
Musculoskeletal Disturbances in calcium–phosphate homeostasis Muscle weakness, pain/aches in muscles and bones, and upper
extremities fracturesa
PTH: parathormone; DEXA: dual energy x-ray absorptiometry; CNS: central nervous system.
aObserved in nonsurgical hypoparathyroidism.
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between 4 and 6 h. The serum calcium concentration
begins to decline approximately 6 h after dosing and
returns to baseline by 16–24 h after each dose. The abso-
lute bioavailability of rhPTH (1–34) is approximately 95%
based on pooled data from 20, 40, and 80 µg doses. The
half-life of rhPTH (1–34) in serum is about 1 h. Systemic
clearance of rhPTH (1–34) exceeds the rate of normal liver
plasma flow, consistent with both hepatic and extrahepatic
clearance. Peripheral metabolism of PTH occurs by nonspe-
cific enzymatic mechanisms in the liver followed by excre-
tion via the kidneys [42].
Varying dose regimens of rhPTH (1–34) have been analyzed
for the treatment of chronic hypoparathyroidism, including
once-daily and twice-daily subcutaneous injections and
administration pump delivery system in adults and children.
The studies conducted with rhPTH (1–34) described effects
including on bone metabolism, BMD, bone architecture, and
quality of life.
3.1.1. Studies with rhPTH (1–34) and effects on
biochemical exams, BMD, and bone tissue
The first study on effects of rhPTH (1–34) on chronic hypopar-
athyroidism was a pivotal randomized crossover trial lasting
20 weeks. This study showed that once-daily injection with
rhPTH (1–34) maintained serum calcium in the normal range
with decreased urine calcium excretion compared with cal-
cium and calcitriol treatment in 10 adult subjects. Markers of
bone turnover levels increased significantly during treatment
with rhPTH (1–34) [22].
Subsequently, a 28-week, randomized crossover trial
comparing once-daily and twice-daily rhPTH (1–34) regi-
mens was conducted in 17 adult patients affected by hypo-
parathyroidism.
During the second half of the day, twice-daily injections of
rhPTH (1–34) increased serum calcium more effectively com-
pared with once-daily rhPTH (1–34). The total daily rhPTH
(1–34) dose was markedly reduced with the twice-daily
regimen and reduces the variation in serum calcium levels
[23]. These results were then reconfirmed in the randomized
crossover trial lasting 28 weeks, which compared two dose
regimens, once daily versus twice-daily rhPTH (1–34), con-
ducted in 14 children with chronic hypoparathyroidism [25].
After these short term trials, Winer et al. conducted two 3-
year, randomized open-label studies to establish the long-
term efficacy of twice-daily PTH compared with conventional
treatment in 27 adults and 12 children with hypoparathyroid-
ism [24,26]. In adults, 27 patients with hypoparathyroidism
were randomized to either twice daily subcutaneously rhPTH
(1–34) or oral conventional therapy with calcitriol and calcium.
Serum calcium concentrations were similar in both treatment
groups, and mean urinary calcium excretion was within the
normal range in rhPTH (1–34)-treated patients, but remained
above normal in the group treated with conventional treat-
ment. Serum and urine bone turnover markers increased sig-
nificantly in rhPTH (1–34) group and peaked at 2–2.5 years.
Over the 3-year study period, bone mineral content and BMD
did not show significant between-group differences. There
was no significant difference in the incidence of adverse
events [24]. Subsequently, a 3-year randomized parallel trial
comparing twice-daily calcitriol plus calcium and cholecalci-
ferol in four daily doses versus twice-daily subcutaneous injec-
tions rhPTH (1–34) treatment was conducted in 12 children
with chronic hypoparathyroidism. In children, mean pre-dose
serum calcium levels were maintained at, or just below, the
normal range, and urine calcium levels remained in the normal
range, with no significant differences between treatment
groups. Markers of bone turnover were mildly elevated during
rhPTH (1–34) therapy and remained within the normal range
during calcitriol therapy. Mean BMD Z-scores at the anterior–
posterior lumbar spine, femoral neck, distal radius, and whole
body remained within the normal range and did not differ
between groups throughout the study. Analysis of symptom
occurrence at any time during the follow-up showed no sig-
nificant differences between groups [26].
Gafni et al. treated five subjects (two adults and three
adolescents) with chronic hypoparathyroidism with rhPTH
(1–34) by injecting two (four patients) to three (one patient)
times daily for 18 months, with doses individualized to main-
tain serum calcium at, or just below, the normal range [29].
Biochemical markers and BMD were assessed every 6 months,
and iliac crest biopsies were performed before and after 1 year
of treatment. rhPTH (1–34) treatment significantly increased
bone markers, and histomorphometry showed that treatment
increased cancellous bone volume and trabecular number and
decreased trabecular separation. Cortical width remained
unchanged; however, rhPTH (1–34) treatment increased corti-
cal porosity. BMD Z-scores were unchanged at the spine and
femoral neck, and total hip Z-scores increased, but total body
BMD Z-scores decreased during the first 6 months of treat-
ment and then stabilized, remaining significantly decreased
compared to baseline. Radial Z-scores also decreased with
treatment [29].
Recently, rhPTH (1–34) was administered as a continuous
infusion by the use of an insulin pump with multi-micropulse
release of the peptide. This particular administration of the
drug allows to mimic the physiologic PTH secretion, which is
about six to seven burst per hour superimposed on an
Studies excluded (not
relevant):
N =59
Articles identified through database search
(MEDLINE 1996-2016) after duplicates
removed:
N =113
Full-text articles
assessed for eligibility:
N = 54
Studies excluded (no met inclusion
criteria):
N = 31
Studies included in 
systemic analysis:
N = 23 
Figure 1. Flow chart for study selection.
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underlying circadian rhythm [43]. A pump delivery system was
compared with twice-daily injections, in order to refine repla-
cement therapy with PTH (1–34) in adults and children [27,28].
The first investigation analyzed eight adult patients with
postsurgical hypoparathyroidism, in a 6-month, open-label,
randomized crossover trial. The use of pump versus twice-
daily delivery of rhPTH (1–34) produced normal and stable
calcium concentrations with minimal fluctuation, without the
rise in serum and urine calcium levels, evident, instead, soon
after rhPTH (1–34) injection. Furthermore, pump delivery nor-
malized bone turnover markers compared with twice-daily
injections. Through 6 months of study, no serious adverse
events occurred. Mean frequency and severity of hypocalce-
mic symptoms did not differ significantly between two groups.
At the end of study, seven of eight patients preferred pump to
twice-daily delivery [27]. Similar results were found in a study
conducted on 12 children and young adults, aged 7–20 years,
with congenital hypoparathyroidism, randomized to receive
rhPTH (1–34), delivered either by twice-daily subcutaneous
injection or insulin pump for 13 weeks [28]. In conclusion,
the marked reduction in urinary calcium excretion, using
rhPTH (1–34) administered by pump, suggests that PTH has
to be continuously exposed to the renal tubule in order for the
renal calcium-conserving effects to be realized. Pump delivery
of rhPTH (1–34) achieved serum calcium, and urine calcium
excretion, and normalization of markers of bone turnover.
These findings were achieved with a smaller daily rhPTH (1–
34) dose compared with the twice daily subcutaneous injec-
tions rhPTH (1–34).
3.1.2. Studies with rhPTH (1–34) and effects on quality of
life
Recently, a 2-year, prospective open-label study showed a
significant improvement in the mean scores of all eight
domains of the Rand 36-Item Short Form Health Survey (SF-
36) in 42 subjects with post surgical hypoparathyroidism trea-
ted with a twice-daily rhPTH (1–34) 20 μg [30]. The main limit
of this study was the absence of control group, and such
results should be reconfirmed.
3.2. Hormone replacement therapy with rhPTH (1–84)
for chronic hypoparathyroidism
rhPTH (1–84) is identical to the full-length human 84-amino
acid protein, and it increases serum calcium concentrations in
a dose proportional manner. The peak plasma concentration
after single subcutaneous injections of rhPTH (1–84) at 50 and
100 µg in subjects affected by hypoparathyroidism occurs
within 5–30 min, followed by a second usually smaller peak
at 1 to 2 h. PTH levels become undetectable by 12 or 24 h [31].
The apparent terminal half-life is 3.02 and 2.83 h for the 50
and 100 µg dose, respectively. The absolute bioavailability is
53%. Currently, no dose adjustment for rhPTH (1–84) is
required for patients with mild-to-moderate renal or hepatic
impairment. The recommended starting dose is 50 µg and,
based on calcemic response, can be titrated at 2- to 4-week
intervals upward to doses of 75 µg and then 100 µg [6].
The studies conducted with rhPTH (1–84) in patients
affected by chronic hypoparathyroidism described effects on
bone metabolism, BMD, bone architecture, bone fractures, and
quality of life.
3.2.1. Studies with rhPTH (1–84) and effects on biochemical
exams, BMD, and bone tissue
Rubin et al. investigated, in an open-label study lasting
24 months, the use of the rhPTH (1–84) in a fixed dose of
100 μg every other day by subcutaneous injection in 30 adult
subjects with chronic hypoparathyroidism. Requirements for
calcium and calcitriol supplements decreased significantly,
respectively, by 45% and 41%. Serum calcium levels and 24-
h urinary calcium excretion were mostly unchanged at
24 months. BMD increased at the lumbar spine by 2.9 ± 4%
from baseline, while femoral neck BMD remained unchanged
and distal one third radial BMD decreased by 2.4 ± 4%.
Transient, mild hypercalcemia occurred sporadically and not
time dependent or dose dependent, although it must be
considered that blood sampling was performed 48 h after
the last PTH injection, and therefore, there might have been
missed a substantial numbers of episodes with hypercalce-
mia [10].
Sikjaer et al. conducted a randomized double-blind study,
in which 62 patients with chronic hypoparathyroidism were
treated with rhPTH (1–84) 100 µg daily or similar placebo for
24 weeks as add-on therapy to conventional treatment.
Compared with placebo, patients with rhPTH (1–84) reduced
their daily dose of calcium and active vitamin D significantly
by 75% and 73%, respectively, without developing hypocalce-
mia. However, hypercalcemia occurred frequently during the
downtitration of calcium and active vitamin D. Compared with
placebo, rhPTH (1–84) treatment reduced significantly the
need for calcium and active vitamin D, whereas plasma cal-
cium and phosphate levels are maintained within the physio-
logic range. rhPTH (1–84) decreased BMD at the hip, lumbar
spine, and whole body but not at the forearm, due, most
likely, to the markedly increased bone turnover [12].
Cusano et al. studied the effect of 4 years of rhPTH (1–84)
treatment (administered at a starting dose of 100 µg subcuta-
neous every other day) in 27 adults with chronic hypopar-
athyroidism [13], through an open-label study without control
group. rhPTH (1–84) reduced the dose of calcium and calcitriol
supplements, respectively, by 37% and 45%, and seven sub-
jects were able to stop totally calcitriol. Serum calcium levels
remained stable, and reductions in urinary calcium excretion
were more variable and not constant over time and fell sig-
nificantly below baseline during years 1, 2, and 3. Lumbar
spine BMD increased by 5.5 ± 9% at year 4, and femoral
neck and total hip BMD remained stable, whereas at year 4,
distal radius BMD was not different from baseline. Bone turn-
over markers increased significantly from baseline values at
6–12 months, subsequently declining to steady-state levels at
30 months. During the study period, 11 episodes of mild
hypercalcemia in eight subjects (1.9% of all values) were
described, most were resolved with adjustment of calcium
and vitamin D supplements [13].
In a double-blind, placebo-controlled, randomized phase III
study, lasting 24 weeks named ‘REPLACE,’ 134 patients with
hypoparathyroidism were randomly assigned to 50 μg/day of
rhPTH (1–84) or placebo [32]. The dose of rhPTH (1–84) could
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be titrated up from 50 to 75 μg and then to 100 μg. Compliance
with injection was excellent for both groups. The 53% of
patients treated with rhPTH (1–84), compared with 2% in the
placebo group, achieved the 50% or greater reduction from
baseline in their daily dose of oral calcium and active vitamin D,
maintaining a normal serum calcium concentration. In rhPTH
(1–84) group, the mean dose of oral calcium supplement and
active vitamin D decreased, respectively, by 52% and 78%, and
albumin-corrected serum calcium concentrations increased at
the start of treatment, whereas urinary calcium excretion
showed a slight decrease. On the other hand, in placebo
group, total serum calcium concentrations fell rapidly and
remained close to the lower end of the target range, and
mean urinary calcium excretion rate also decreased. Mean
serum phosphate levels were similar, at the upper limit of
normal, in both groups at baseline, but decreased in the
group treated with rhPTH (1–84) and remained lower than in
the placebo group. The overall incidence of adverse events was
similar in both groups, treated with rhPTH (1–84) and placebo
group. In the rhPTH (1–84) group, only one serious adverse
event, characterized by hypercalcemia, was regarded as treat-
ment related. During the treatment period, hypocalcemia was
reported as an adverse event in 23 (26%) patients in the rhPTH
(1–84) group (43 events) compared with 9 (21%) patients in the
placebo group (9 events) [32].
Subsequently, a 24-week, open-label, flexible-dose exten-
sion study of REPLACE, named ‘REPEAT,’ has been conducted
[40]. Patients, who previously completed or enrolled in
REPLACE, received rhPTH (1–84), 50 μg/day, escalated to 75
and then to 100 μg/day, if necessary. The primary end point
was ≥50% reduction in oral calcium (or ≤500 mg/day) and
active vitamin D (or calcitriol ≤0.25 μg/day or alfacalcidol
≤0.50 μg/day), maintaining normal calcium levels. Twenty-
four patients were enrolled and completed the study. At
study end, 75% of patients achieved the study end point,
and 58% eliminated oral calcium and active vitamin D.
Urinary calcium, serum phosphate, and calcium–phosphate
product decreased by the study end, and mean serum bone
turnover markers increased with rhPTH (1–84). During this
study, any serious adverse events were described [40].
Two other studies with rhPTH (1–84) have been conducted.
RELAY is a short, 8-week, double-blind, multinational rando-
mized trial that tested whether doses as low as 25 µg/day
could be efficacious in patients affected by hypoparathyroid-
ism [18,44]. Although some subjects were able to meet the
primary end point (oral calcium not more than 500 mg/day
and active vitamin D not more than 0.25 µg/day), most
patients did not, confirming the results of the REPLACE trial
that most patients require an amount of rhPTH (1–84) more
than 50 µg/day. The other recent study, called RACE, is an
open-label extension of the REPLACE and RELAY trials con-
ducted in the USA [18]. The initial results at 1 year provide
confirmatory evidence of the primary end points of the
REPLACE trial, carried out for 1 year [18].
Recently, 124 adult patients belonging to the study
REPLACE were analyzed to determine the effect of rhPTH
(1–84) (50 µg/day, titrated to 75 and then to 100 µg/day, to
permit reductions in oral calcium and active vitamin D doses
while maintaining serum calcium within 2.0–2.2 mmol/L) on
phosphate and vitamin D metabolite levels [33]. Serum
phosphate levels decreased rapidly from the upper
normal range and remained lower with rhPTH (1–84). At
week 24, serum calcium–phosphate product was lower
with rhPTH (1–84) versus placebo. After 24 weeks, 1,25(OH)
2D3 levels were unchanged in both treatment groups,
despite significantly greater reductions in active vitamin D
dose in the rhPTH (1–84) group [33].
At last, Rubin et al. has published an interesting prospective
open-label study of 33 patients with hypoparathyroidism,
treated with rhPTH (1–84) subcutaneous injections, with a
starting dose of 100 µg every other day, lasting 6 years, with-
out control group [41]. This study is the longest clinical experi-
ence with PTH treatment available so far in the management
of hypoparathyroidism. The use of a long-term, continuous
therapy with rhPTH (1–84), in this population, described a
significant reduction of calcium and calcitriol requirements,
maintaining stable and normal serum calcium levels and redu-
cing urinary calcium excretion (urinary calcium excretion fell
significantly below pretreatment levels at years 1, 3, and 6).
Serum phosphate decreased significantly from baseline at
years 4 and 5, but year-6 levels were similar to baseline values.
Lumbar spine and total hip BMD increased, whereas femoral
neck BMD remained stable and the distal one-third radius
decreased. Bone turnover markers increased significantly and
subsequently declining but remaining higher than pretreat-
ment values [41]. Histomorphometric studies of bone biopsies,
performed after 2 years, showed that trabeculae were thinner
and more numerous, and there was an increase in cortical
porosity [36]. The salutary effects on microarchitecture and
bone size could provide biochemical advantages at cortical
bone despite a decrease in BMD. This study has demonstrated,
although in a small sample, a good safety regarding the con-
trol of calcium homeostasis (12 hypercalcemic events in 9
subjects; 2.5% of all values), without hypercalcemic events
requiring hospitalization. The most common serious adverse
event was hypocalcemia (five times in three patients), and
other adverse events included eight fractures in six
patients [41].
Regarding effect of rhPTH (1–84) on bone tissue, Sikjaer
et al. assessed effects of rhPTH (1–84) on 3D bone structure
[34]. The study involved randomized 62 patients with chronic
hypoparathyroidism into 24 weeks of treatment with either
rhPTH (1–84) 100 µg/day subcutaneously or similar placebo as
an add-on therapy. Micro-computed tomography (μCT) was
performed on 44 iliac crest bone biopsies (23 on PTH treat-
ment) obtained after 24 weeks of treatment. Compared with
placebo, PTH caused a 27% lower trabecular thickness
(p < 0.01) and 4% lower trabecular bone tissue density
(p < 0.01), whereas connectivity density was 34% higher
(p < 0.05). Trabecular tunneling was evident in 11 (48%) of
the biopsies from the PTH group. At cortical bone, the number
of Haversian canals per area was 139% higher (p = 0.01) in the
PTH group, causing a tendency toward an increased cortical
porosity (p = 0.09). At different subregions of the hip, areal
BMD (aBMD) and vBMD, as assessed by DXA and QCT,
decreased significantly by 1–4% in the PTH group. However,
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at the lumbar spine, aBMD decreased by 1.8% (p < 0.05),
whereas vBMD increased by 12.8% (p = 0.02) in the PTH
compared with the placebo group [34].
Recently, an interesting study has been conducted on restora-
tion of the euparathyroid state associated with improvement of
bone dynamics both in hypoparathyroidism and in primary
hyperparathyroidism [45]. The study investigated changes in
BMD and trabecular bone score with restoration of the eupar-
athyroid state by parathyroidectomy in primary hyperparathyr-
oidism or rhPTH (1–84) in hypoparathyroidism. This was a 2-year
prospective intervention study in which the authors evaluated
aBMD by DXA and trabecular bone score in 52 hypoparathyroid
patients treated with rhPTH (1–84) and 27 patients with primary
hyperparathyroidism who underwent parathyroidectomy.
Treatment with rhPTH (1–84) was associated with significant
increases of aBMD in lumbar spine and decreases in distal one-
third radius by 18 months in hypoparathyroid patients. At this
time point, hypoparathyroid subjects demonstrated a significant
increase in trabecular bone score frombaseline, while there were
no significant changes in trabecular bone score following para-
thyroidectomy. BMD increases with both administration of PTH
in a state of PTH deficiency or removal of PTH in a state of PTH
excess, but only hypoparathyroid patients treatedwith rhPTH (1–
84) appeared to have improvements in microarchitectural pat-
tern as assessed by trabecular bone score [45].
At last, recently, Rubin et al. utilized direct 3D microstruc-
tural analysis to determine the extent to which bone changes
such as reduced trabecular thickness and an increase in tra-
becular number may be related to bone strength [37]. Iliac
crest bone biopsies from 58 hypoparathyroid subjects were
analyzed by μCT and by microfinite element analysis. Biopsies
were performed at baseline and at 1 or 2 years of rhPTH (1–
84). After 1 year of treatment with rhPTH (1–84), force (the
maximum load sustained, in the long axis of the biopsies) and
Young's modulus (an index of resistance to compressive
forces) tended to increase. The 1-year change in cancellous
mineralizing surface predicted 1-year changes in μCT variables.
The biopsies obtained after 2 years of rhPTH (1–84) showed no
change from baseline. The results indicated that rhPTH (1–84)
improved skeletal quality in hypoparathyroid early in treat-
ment [37].
3.2.2. Studies with rhPTH (1–84) and effects on quality of life
Cusano et al. tested the improvement in quality of life mea-
sures through 5 years with rhPTH (1–84) therapy in 69 hypo-
parathyroid patients, receiving open-label rhPTH (1–84).
Before and during therapy, subjects completed the SF-36.
rhPTH (1–84) therapy was associated with improvement in
mental and physical health as determined by the SF-36 metric
[38], confirming the results obtained in the previous study
conducted on 54 hypoparathyroid subjects receiving open-
label rhPTH (1–84) for 12 months [39]. However, both studies
did not have control group. On the other hand, a placebo-
controlled study conducted on 62 patients with chronic hypo-
parathyroidism [randomized to 6 months of treatment with
either rhPTH (1–84) 100 μg/day or placebo, given as add-on
therapy to conventional treatment] did not demonstrate
improvement in quality of life in rhPTH-treated group, evalu-
ated with SF-36 and WHO-5 Well Being Index [35].
3.3. Risk of osteosarcoma, potential adverse events, and
the use of rhPTH
Osteosarcoma is a rare bone cancer, which mainly affects
adolescents and young adults. Though lower-grade variants
exist, most are high-grade malignancies with a high propen-
sity for lung metastases [46]. The occurrence of osteosarcoma
was described in a study conducted on rats treated with PTH.
The increased incidence of osteosarcoma in rats could be
justified by the use of the doses of PTH much higher than
systemic exposure described in humans and by the different
bone homeostasis and physiology in rats [47,48]. No signals
have emerged to suggest that human subjects treated with
either forms of PTH are at increased risk for the development
of osteosarcoma, during the clinical human experience with
rhPTH (1–34) and with rhPTH (1–84, 49). Only a handful of
cases of osteosarcoma have appeared in patients exposed to
rhPTH (1–34), a number that is below what would be expected
on the basis of epidemiological considerations of the back-
ground incidence of osteosarcoma in human subjects. In the
ongoing surveillance registry of osteosarcoma, there is no
evidence that any subject with osteosarcoma had ever been
exposed to rhPTH (1–34) [49].
Up to now, regarding the main adverse events during
treatment with rhPTH, the controlled and cohort studies
have reported hypercalcemia episodes, although less pro-
nounced and of shorter duration compared with conventional
treatment [10,12,22,26]; hypocalcemia episodes, including
only three cases of severe hypocalcemia [13]; bone pain
[12,23,24]; and nephrolithiasis, reported only in one case,
developed despite normal serum calcium concentrations [13].
4. Conclusions
Summarizing, the studies conducted on rhPTH (1–34) were the
first to use the rhPTH to treat hypoparathyroidism. Randomized,
open-label crossover trials demonstrated that injections of
rhPTH (1–34) twice-a-day showed a good control of serum
calcium levels compared with conventional therapy, but did
not show a significant reduction in 24-h urinary calcium excre-
tion compared to standard therapy with calcium and calcitriol
supplements, in patients affected by chronic hypoparathyroid-
ism [24,26]. On the other hand, the studies with rhPTH (1–34)
therapy, delivered by an infusion pump, showed a near normal-
ization of the diurnal rhythm of serum calcium and phosphate
levels, a significant reduction of 24-h urinary calcium excretion,
and markers of bone turnover normalized, compared with
twice-a-day injections subcutaneous of rhPTH (1–34).
Moreover, the total daily rhPTH (1–34) dose required to main-
tain normocalcemia was reduced [27,28]. Compared with twice-
daily administration, pump delivery of rhPTH (1–34) provided
more physiologic calcium homeostasis and bone turnover. BMD
measurements remained stable over the 3-year study period
[27,28]. Regarding the effect on quality of life, recently, an
open-label trial of rhPTH (1–34) in 42 adult patients with
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postsurgical hypoparathyroidism showed improvement regard-
ing this aspect, but there was not a control group [30]. The
limits of these studies were as follows: no longer duration than
3 years, small patient samples, and lack of double-blind rando-
mized trials. Moreover, the trials conducted by Winer et al.
originated from a single-center, posing a sampling bias.
On the other hand, rhPTH (1–84) provides the natural
hormone, lacking in this disorder, and has an effective half-
life longer than rhPTH (1–34). The studies showed that this
drug permits an important reduction in the need for calcium
and active vitamin D supplements, maintaining normal mean
calcium levels compared to conventional therapy, but only
transient reductions in urinary calcium excretion [32,41].
Regarding the effects on BMD, a tendency of increase on
lumbar spine and total hip BMD, whereas femoral neck BMD
remained stable and the distal one-third radius decreased,
together with an increase of bone turnover markers [41]. A
beneficial effect of rhPTH (1–84) in terms of quality of life was
described, as showed by the evaluation of SF-36 scale in
hypoparathyroid patients [38]; on the other hand, another
protocol did not demonstrate the same improvement in qual-
ity of life [35].
5. Expert opinion
The studies, conducted up to now, have shown that rhPTH can
be an attractive treatment option for subjects affected by
chronic hypoparathyroidism, which are unable to control sta-
bly serum calcium concentrations, requiring very large
amounts of calcium and active vitamin D with the associated
risks of serious long-term complications. However, currently,
only the use of rhPTH (1–84) was approved by the FDA, in the
USA, with a ‘black box’ warning because of the potential risk
of osteosarcoma [5,6], and further investigations, especially
randomized controlled trials, should be conducted with large
samples of patients and for a long period in order to evaluate
long-term efficacy and safety of rhPTH treatment.
rhPTH (1–84) and rhPTH (1–34), the latter especially deliv-
ered by an infusion pump, are able to reduce the dosage of
supplements with calcium and vitamin D maintaining normal
mean serum calcium levels. However, rhPTH is not capable to
mimic exactly the physiological PTH levels and the physiolo-
gical regulation of calcium–phosphate homeostasis during
24 h. Probably, in the future, other dosages and mode of
administration could be studied. Moreover, in the coming
years, further long-term investigations are necessary to evalu-
ate the effects of rhPTH therapy on urine calcium excretion in
order to clarify its effect, since, up to now, it has shown only
transient reduction. Moreover, rhPTH treatment, because of its
mechanism of action, has also a potential preventive role for
other complications, such as renal complications, extraskeletal
calcifications, or regarding other organs involved in the dis-
ease, but long term studies should be conducted to evaluate
the real effects of rhPTH on these complications, comparing
conventional treatment.
Both the real risk of fracture due to chronic hypoparathyr-
oidism disease and the impact of rhPTH treatment should be
clarified. In this regard, it should be properly deepened and
clarified the long term effect of rhPTH on BMD changes, bone
strength, and bone quality.
The treatment with rhPTH tends to increase both bone
formation markers, and as suggested by Rubin et al. [50],
this may indirectly reflect a recovery of osteoblast function
by means of both increased cell differentiation and decreased
preosteoblast and osteoblast apoptosis, but also bone resorp-
tion markers, resulting in an overall increase in bone turnover
compared to conventional therapy. The marked increase in
bone turnover may induce a ‘renewal’ of the overmineralized
bone that is typically observed in a state of chronic hypopar-
athyroidism, inducing a more physiological bone metabolism
[36]; however, these aspects should be clarified.
Regarding the effects on BMD, contrasting data are
reported in literature. Indeed, studies with rhPTH (1–34)
showed that BMD levels maintained stable over 3 years
[24,26] and with rhPTH (1–84) showed a tendency for lumbar
spine and total hip BMD to increase, whereas femoral neck
BMD remained stable and the distal one-third radius
decreased over 6 years, in addition to an increase of bone
turnover markers [41,45]. On the other hand, Sikjaer et al.
described decreased BMD at the hip, lumbar spine, and
whole body but not at the forearm after 24 weeks of treat-
ment with rhPTH (1–84) compared with placebo [12]. These
results could be explained by differential effects of rhPTH on
bone metabolism according to different doses and number of
daily administration because PTH is more catabolic compared
to the intermittent dosing. Moreover, regarding the effect on
bone microarchitecture by rhPTH (1–84), the study by Sikjaer
et al. assessed this aspect using μCT on iliac crest bone biop-
sies [34]. This analysis showed that rhPTH (1–84), compared
with placebo, caused a lower trabecular thickness and lower
trabecular bone tissue density, whereas connectivity density
was higher, indicating a better connected trabecular network
in the PTH-treated patients and a tendency toward an
increased cortical porosity. However, because the trabecular
separation did not differ between the two groups, the higher
connectivity density was probably caused by the trabecular
tunneling in the rhPTH-treated patients [34]. These micro-
architectural changes could improve bone quality [37]; how-
ever, further long-term investigations should be performed.
rhPTH treatment has also a potential role on improvement
of quality of life, but, up to now, only three open-label studies,
without control group (two with rhPTH (1–84) and one with
rhPTH (1–34)) showed an improvement regarding this issue
[30,38,39]. On the other hand, a placebo-controlled study
conducted on 62 hypoparathyroid patients did not show
improvement of quality of life parameters [35]. Therefore,
long-term effects regarding quality of life and neurocognitive
function require further studies. It is clear that impaired quality
of life can be associated with chronic hypoparathyroidism, but
it must still be clarified whether impairment of well-being
results directly from only PTH deﬁciency without or with the
involvement of changes in calcium homeostasis and the role
of PTH in the central nervous system. Moreover, further stu-
dies are necessary to create adequate methods for assessing
quality of life in these particular patients in order to monitor
this parameter over time and demonstrate the effect of treat-
ment on this aspect.
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Concerning safety profile of rhPTHdata derivedby randomized,
open-label crossover studies with rhPTH (1–34) [23–26], rando-
mized, double-blind placebo-controlled study with rhPTH (1–84)
[32] and data in cohorts of subjects treated with rhPTH (1–84) for
4–6 years [13,41] have not raised any safety concerns. Episodes of
hypercalcemia can occur during the first fewmonths of treatment
with rhPTH, but usually it is readily corrected with titration of the
patient’s supplementation regimen. The prospective 6-year inves-
tigation on efficacy and safety of rhPTH (1–84) showed that many
adverse events, such as nausea; headache; musculoskeletal disor-
ders; fatigue; dizziness; neurological,mental, andmoodalterations;
paresthesia; and increased urination, tended to decrease during
treatment with rhPTH (1–84) [41]. However, further investigations
are necessary. Currently, safety and efficacy of rhPTH (1–84) have
not been described in patients <18 years of age. This drug is
avoided in case of pediatric and young adult hypoparathyroid
subjects with open epiphyses, considering the increased baseline
risk for osteosarcoma [6]. Regarding patients aged 65 and over,
there are no sufficient clinical studies that describe the response to
this drug in these subjects compared to younger subjects.
Therefore, caution is recommended in increasing the dosage in
elderly patients [6]. For both drugs, the studies have shown a good
compliance and a high tolerance.
There are no studies that directly compare rhPTH (1–84)
and rhPTH (1–34). The studies conducted had variable subjects
and methods, and this heterogeneity makes difficult the com-
parison. However, rhPTH (1–84) could be considered more
attractive than rhPTH (1–34), as replacement hormone ther-
apy, because the full-length peptide is exactly what is missing
in this disease and its effective half-life longer than rhPTH (1–
34). Moreover, the results derived by studies with rhPTH (1–84)
for treatment of chronic hypoparathyroidism have been con-
ducted with a longer duration and with more patients com-
pared with studies conducted with rhPTH (1–34).
At last, deciding on the target patient group for rhPTH is
essential, considering also the cost of this treatment. In this
regard, a recent guideline recommends taking into consid-
eration rhPTH (1–84) therapy in any patient with well-estab-
lished chronic hypoparathyroidism of any etiology, in
particular, in case of variable and inconstant control of the
serum calcium with frequent episodes of hypo- and hyper-
calcemia; oral calcium/vitamin D medications required to
control the serum calcium or symptoms that exceed 2.5 g
calcium or >1.5 μg active vitamin D; hypercalciuria; renal
stones; nephrocalcinosis; stone risk; or reduced creatinine
clearance or eGFR (estimated glomerular filtration rate)
(<60 mL/min); hyperphosphatemia and/or calcium–phos-
phate product that exceeds 55 mg2dL2 (4.4 mmol2L2); gas-
trointestinal tract disorder that is associated with
malabsorption; and, finally, reduced quality of life [2].
In the future, new possible therapeutic approaches could
be studied; in this regard, recently, a study has described the
pharmacological properties of PCO371, a novel orally active
small molecule that acts as a full agonist of PTH type 1
receptor (PTHR1), a class B G-protein-coupled receptor. In
hypocalcemic rats, PCO371 restores serum calcium levels with-
out increasing urinary calcium and with stronger and longer-
lasting effects than PTH injections. These results can suggest
that PCO371 can provide a new treatment option for PTH-
related disorders, including hypoparathyroidism, but of
course, more studies need to be performed [51].
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